Ocular TherapeutixFRA:0OT -1.18%51 Gross Margin % is 87.67% as of Mar. 2026, which is 0% below its 10-year median of 87.69. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.73 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, Ocular Therapeutix ranks better than 79.59% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ocular Therapeutix had a gross margin of 87.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ocular Therapeutix Gross Margin % Related Terms
Ocular Therapeutix Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0OT vs NKTR, PVLA, GENB: Gross Margin % Comparison
For the Biotechnology subindustry, Ocular Therapeutix's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ocular Therapeutix (FRA:0OT) has a Gross Margin % of 87.67% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Ocular Therapeutix and its competitors. This is near median its historical median of 87.69. Over the past decade, Ocular Therapeutix's Gross Margin % has ranged from 45.00 to 91.18. According to the industry distribution chart, Ocular Therapeutix ranks #150 out of 735 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Ocular Therapeutix's Gross Margin % too high?
Ocular Therapeutix's current Gross Margin % of 87.67% is near median its 10-year median of 87.69. Over the past 10 years, this metric has ranged from a low of 45.00 to a high of 91.18. The Biotechnology industry median Gross Margin % is 60.90. Ocular Therapeutix's value of 87.67% is 44% above this industry median. Based on the distribution chart, Ocular Therapeutix ranks #150 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Gross Margin % compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #150 out of 735 companies for Gross Margin %. This places Ocular Therapeutix in the top 20% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Ocular Therapeutix's value of 87.67% is 44% above this benchmark. Historically, Ocular Therapeutix's own Gross Margin % has ranged from 45.00 to 91.18 over the past decade. While the company's 10-year median is 87.69 vs. the industry median of 60.90, Ocular Therapeutix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocular Therapeutix's current Gross Margin % of 87.67% is 44% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current Gross Margin % is 87.67%, which is near median its own 10-year median of 87.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.73, compared to a current price of €8.35 — trading 123.9% above its estimated fair value. The current Gross Margin % is 87.67%, which is near median its 10-year median of 87.69 and 44% above the Biotechnology industry median of 60.90. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Gross Margin % is 87.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of €8.35 is trading 123.9% above its estimated GF Value™ of €3.73.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for FRA:0OT:
Gross Margin %: 87.67% (near median its 10-year median of 87.69)
GF Value™: €3.73 vs. price of €8.35 (123.9% above fair value)
Industry Position: 44% above the Biotechnology median (#150 of 735)
No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score
Get the complete analysis for FRA:0OT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0OT has been successfully added to your 
